Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:41 PM
Ignite Modification Date:
2025-12-24 @ 5:41 PM
NCT ID:
NCT06331468
Eligibility Criteria:
Inclusion Criteria:
* Untreated, pathologically or cytologically-confirmed diagnosis of FIGO Stage IB3, II, or IIIA-IIIC1 bulky ( ≥ 6cm) or Stage IVB (FIGO 2018) squamous, adenosquamous, or adenocarcinoma of the uterine cervix with limited metastatic burden (not requiring urgent systemic therapy).
* Adequate organ and marrow function
* Gynecologic Oncology Group performance status of 0, 1, or 2
* Patient agrees to use two forms of birth control if they are of child-bearing potential
* Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
* Presence of another concurrent active invasive malignancy
* Prior invasive malignancy diagnosed within the last three years, with the following two exceptions: \[a\] non-melanoma skin cancer and/or \[b\] prior in situ carcinoma of the cervix
* Receipt of prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues, at the discretion of the treating physician
* Currently receiving any other investigational agent(s) for the treatment of cancer
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Cisplatin or other agents used in study
* Presence of uncontrolled intercurrent illness as determined by the treating physician
* pregnant or lactating
* Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
120 Years
Study:
NCT06331468
Study Brief:
Protocol Section:
NCT06331468